{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:04:47Z","timestamp":1760015087369,"version":"3.40.5"},"reference-count":24,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s412079","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T04:00:13Z","timestamp":1694404813000},"page":"673-680","source":"Crossref","is-referenced-by-count":1,"title":["Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Morie","family":"Gertz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafat","family":"Abonour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-642X","authenticated-orcid":true,"given":"Sarah","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7534-2207","authenticated-orcid":true,"given":"Muriel","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Landau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Mahindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Quock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":true,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha","family":"Tuchman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6035-2815","authenticated-orcid":true,"given":"Irina","family":"Yermilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-5536","authenticated-orcid":true,"given":"Michael","family":"Broder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.jcmg.2019.06.023","volume":"12","author":"Fontana","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2217\/cer-2017-0100","volume":"7","author":"Quock","year":"2018","journal-title":"J Comp Eff Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1182\/blood-2021-146983","volume":"138","author":"Quock","year":"2021","journal-title":"Blood"},{"key":"ref7","unstructured":"NIH National Library of Medicine. Claims Data. Accessed April 5, 2022. https:\/\/www.nlm.nih.gov\/nichsr\/stats_tutorial\/section3\/mod3_data.html."},{"key":"ref8","unstructured":"DARZALEX (daratumumab) - Prescribing Information."},{"key":"ref9","unstructured":"DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis. Content Lab U.S. 2021. https:\/\/www.jnj.com\/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-becomes-the-first-fda-approved-treatment-for-patients-with-newly-diagnosed-light-chain-al-amyloidosis."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2105\/AJPH.74.9.979","volume":"74","author":"Fink","year":"1984","journal-title":"Am J Public Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1287\/mnsc.9.3.458","volume":"9","author":"Dalkey","year":"1963","journal-title":"Manag Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1017\/S0266462300002774","volume":"2","author":"Brook","year":"1986","journal-title":"Int J Technol Assess Health Care"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/JHL.S352500","volume":"14","author":"Broder","year":"2022","journal-title":"J Healthc Leadersh"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/0272989X211028236","volume":"42","author":"Bojke","year":"2022","journal-title":"Med Decis Making"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41408-020-0306-5","volume":"10","author":"Sidana","year":"2020","journal-title":"Blood Cancer J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"ref17","unstructured":"Research C for DE. FDA approves daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone for multiple myeloma. FDA; 2021. Accessed September 14, 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-daratumumab-and-hyaluronidase-fihj-pomalidomide-and-dexamethasone-multiple-myeloma."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00277-012-1530-2","volume":"91","author":"Blommestein","year":"2012","journal-title":"Ann Hematol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ajh.25819","volume":"95","author":"Gertz","year":"2020","journal-title":"Am J Hematol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s41669-019-0122-7","volume":"3","author":"McCausland","year":"2019","journal-title":"PharmacoEconomics - Open"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJM199806253382607","volume":"338","author":"Shekelle","year":"1998","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s12350-017-0917-9","volume":"24","author":"Patel","year":"2017","journal-title":"J Nucl Cardiol off Publ Am Soc Nucl Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM200103013440906","volume":"344","author":"Hemingway","year":"2001","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2105\/ajph.77.2.187","volume":"77","author":"Merrick","year":"1987","journal-title":"Am J Public Health"}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=92663","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=92663","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T04:00:20Z","timestamp":1694404820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/using-a-modified-delphi-panel-to-estimate-health-service-utilization-f-peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":24,"URL":"https:\/\/doi.org\/10.2147\/ceor.s412079","relation":{},"ISSN":["1178-6981"],"issn-type":[{"type":"electronic","value":"1178-6981"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}